**SCIENTIFIC SESSION**
**NRG ONCOLOGY RESEARCH REVIEW**

**Friday, February 11, 2022**
**12:00 pm - 1:30 pm ET**

### SPEAKERS

**Patricia A. Ganz, MD**

Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer (NSABP B-55)

**Spring Kong, MD**

NRG-RTOG 1106/ACRIN 6697: A phase IIIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC — Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation)

**Benjamin Movsas, MD**

Dose Escalated Radiotherapy (RT) Alone or in Combination with Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) from the NRG Oncology/RTOG 0815 Randomized Trial

**Daniel Krauss, MD**

Dose escalated radiotherapy alone or in combination with short-term androgen suppression for intermediate risk prostate cancer: outcomes from the NRG Oncology/RTOG 0815 randomized trial

**Jeanne Carter, PhD**

The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function.

**Linda Mileshkin, MD**

Adjuvant chemotherapy following chemo-radiation as primary treatment for locally advanced cervical cancer compared to chemo-radiation alone: The randomised phase 3 OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274)